Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E17.76 EPS (ttm)9.77 Insider Own0.20% Shs Outstand748.36M Perf Week1.25%
Market Cap129.86B Forward P/E13.91 EPS next Y12.48 Insider Trans-2.37% Shs Float747.47M Perf Month1.94%
Income7.43B PEG2.24 EPS next Q2.80 Inst Own81.20% Short Float1.07% Perf Quarter20.72%
Sales22.47B P/S5.78 EPS this Y35.20% Inst Trans-0.53% Short Ratio2.81 Perf Half Y17.52%
Book/sh40.12 P/B4.33 EPS next Y9.83% ROA10.10% Target Price190.56 Perf Year28.35%
Cash/sh46.81 P/C3.71 EPS next 5Y7.93% ROE25.90% 52W Range126.96 - 176.85 Perf YTD8.98%
Dividend4.00 P/FCF21.69 EPS past 5Y13.60% ROI12.50% 52W High-3.30% Beta0.94
Dividend %2.31% Quick Ratio3.70 Sales past 5Y7.60% Gross Margin81.40% 52W Low34.70% ATR2.71
Employees17900 Current Ratio4.00 Sales Q/Q5.90% Oper. Margin40.70% RSI (14)47.50 Volatility1.19% 1.49%
OptionableYes Debt/Eq1.10 EPS Q/Q14.90% Profit Margin33.10% Rel Volume1.36 Prev Close173.53
ShortableYes LT Debt/Eq0.93 EarningsOct 27 AMC Payout36.30% Avg Volume2.85M Price171.02
Recom2.40 SMA20-0.30% SMA500.15% SMA2009.35% Volume3,051,022 Change-1.45%
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Sep-27-16 12:42PM  Why Wells Fargo, Gilead, Newfield, Amgen, and Chesapeake Energy Are Trending at Insider Monkey
12:40PM  Stocks Extend Gains; Facebook Up On Positive Analyst Chatter
11:54AM  Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade
11:38AM  Stocks Up After 1st Presidential Debate; Why Tesla Looks Healthiest In Weeks
11:23AM  The Drug Price Increase Debate: Separating The Winners From The Losers
11:15AM  Amgen (AMGN) Stock Slides, RBC: Clarion Trial May Have Failed Due to Design
11:00AM  Amgen's multiple myeloma drug falls short in new-patient study Reuters
10:44AM  Amgen: The Blame Game at
10:12AM  Amgen/UCB's BLA for Osteoporosis Drug Accepted in the U.S.
08:30AM  Amgen Inc Investor Conference Call to discuss CLARION Data scheduled for 8:30 am ET today
08:23AM  Biosimilars in Limelight on FDA Approval of Amgen Drug
07:50AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
06:27AM  Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients
05:13AM  Amgen's multiple myeloma drug falls short in late stage study Reuters
04:00AM  Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients PR Newswire
Sep-26-16 05:00PM  Amgen Opens Nomination Process For LabCentral Residency PR Newswire
04:03PM  Wall Street Sells Off on Worries Over Clinton-Trump Showdown
04:00PM  Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab PR Newswire
02:38PM  Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
02:20PM  As Humira Alternative Gets FDA Approval, Is Abbvie in Trouble?
01:53PM  Amgens Venture Funding Initiative (AMGN) at Investopedia
10:05AM  And Then Theres Mylans Specialty Segment, Home of the EpiPen
08:15AM  How Much Will Consumers Save on New Humira Biosimilar? at 24/7 Wall St.
08:01AM  3 Trades to Blaze a Trail Higher in Amgen
06:49AM  Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval
Sep-24-16 01:00AM  [$$] Biotech Is Cheaper Than Big Pharma at
Sep-23-16 07:42PM  FDA Approves Amgen's Biosimilar Version of Humira at The Wall Street Journal
06:22PM  FDA approves lower-cost alternative to biotech drug Humira
06:03PM  FDA Approves Amgen's AMJEVITA (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases PR Newswire
05:50PM  U.S. FDA approves Amgen's copy of AbbVie arthritis drug Humira Reuters
05:05PM  Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar?
04:44PM  U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira
11:38AM  Top 5 profitable Biotech stocks : September 23, 2016
10:04AM  What Are Analysts Recommendations for Gilead Sciences?
06:17AM  [$$] Biotech Is Cheaper Than Big Pharma: What to Buy at
Sep-22-16 07:00PM  Cramer Remix: Outrunning trading algorithms with the clic...
09:56AM  New Setback for Sanofi's Lantus Increases Need for M&A
Sep-21-16 10:47AM  Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
10:05AM  Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment
Sep-20-16 03:24PM  Romosozumab From Amgen Inc (AMGN) Shows Positive Results In Osteoporosis at Insider Monkey
12:09PM  The 5 Top-Selling Drugs In The World
11:04AM  Teva, Eli Lilly Have Migraine Treatments in Trial Phases
10:05AM  Alder BioPharmaceuticalss Migraine Therapy Shows Promise
09:00AM  Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab) PR Newswire
08:05AM  Entering Migraine Market Wont Be Easy for Novartis, Amgen
Sep-19-16 01:06PM  Amgen-Servier Collaboration Commercializes Chronic Heart Therapy Globally (AMGN) at Investopedia
11:30AM  Amgen Inc Conference Call to Discuss the results from the romosozumab phase 3 postmenopausal osteoporosis study scheduled for 11:30 am ET today
11:07AM  Amgen Products Threatened by Court Losses (AMGN) at Investopedia
10:38AM  Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
08:25AM  RBC Says These 4 Top Biotechs Could Have Big Upside Potential at 24/7 Wall St.
Sep-18-16 11:00AM  Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis PR Newswire
Sep-17-16 02:06PM  Technical Analysis of Markets 9/16/16
11:41AM  Is This New Market the Biggest Investment Idea of the Decade? at Motley Fool
10:00AM  AMGN: How Amgen's Stock Price Rose 18.55% in 6 Months at Investopedia
Sep-16-16 05:41PM  [$$] Abingworth Seeds Immunotherapy Startup GammaDelta at The Wall Street Journal
03:54PM  Amgen Targeting Biosimilars (AMGN) at Investopedia
12:09PM  Novartis says experimental drug helps chronic migraine sufferers
07:33AM  Amgen Receives Positive CHMP Opinion For Parsabiv (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis PR Newswire
06:54AM  Dr. Reddys Expands Strategic Collaboration with Amgen in India Business Wire
Sep-15-16 04:30PM  Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine PR Newswire
Sep-14-16 06:40PM  Third Avenue Fund Comments on Amgen
04:00PM  Amgen To Webcast Investor Call PR Newswire
01:15PM  Third Avenue Value Fund 3rd Quarter Letter
12:29PM  Amgen, Inc. Value Analysis (NASDAQ:AMGN) : September 14, 2016
12:00PM  Amgen (AMGN) Stock Is Wednesday's 'Chart of the Day'
08:17AM  AbbVie's Battle Royale
Sep-13-16 09:57PM  [$$] Takeda earmarks $15bn for US pharma acquisitions at Financial Times
04:00PM  Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference PR Newswire
01:20PM  Big Pharma Spends Millions to Keep Prices High for California Agencies
10:04AM  Biogen Committed to Bolstering Its Strong Product Pipeline
09:30AM  The Zacks Analyst Blog Highlights: Spectrum Pharmaceuticals, Amgen, AbbVie and Vertex Pharmaceuticals
08:04AM  Product Launches Are Part of Biogens Plans to Boost Revenues
08:04AM  Amgen, Inc. breached its 50 day moving average in a Bullish Manner : AMGN-US : September 13, 2016
07:05AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
12:10AM  [$$] On Bank of Englands Shopping List: Apple, Daimler Bonds at The Wall Street Journal
Sep-12-16 06:45PM  Traders pick biotech stocks as sector sees best day in months at CNBC
05:00PM  Buying biotech: 5 trades in pharma
04:12PM  [$$] On Bank of England's Shopping List: Apple, Daimler Bonds at The Wall Street Journal
03:32PM  Biotech: Four Catalysts for Four Stocks at
11:59AM  Two Things You Must Understand About Biotech Investing at Motley Fool
10:27AM  ETFs with exposure to Amgen, Inc. : September 12, 2016
09:23AM  3 Drug Stocks That Could Benefit from Key FDA Events in Sep 2016
Sep-11-16 08:00PM  Charts Show Something Broke Friday
07:36AM  Fed Members Should Talk Less, Guide Better and Think Globally
Sep-09-16 03:04PM  Market Watches to See if Biogen Will Meet Its Raised Guidance
02:03PM  Here's When You Should Buy Amgen
11:04AM  Analysts Look for Celgene to Offer Striking Returns in 2016
Sep-08-16 04:00PM  Amgen To Present At The Morgan Stanley Global Healthcare Conference PR Newswire
11:29AM  Merck's Lung Cancer Drug Keytruda Under Priority Review
11:04AM  Celgene Carves Out More Share of This Cancer Treatment Market
10:04AM  What Are the Possible Threats to Revlimid?
08:08AM  3 Attractive Income Stocks Whose Dividends Could Double at Motley Fool
Sep-07-16 04:13PM  Goldman's 7 Favorite Biotech Ideas For 2016
04:00PM  Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting PR Newswire
02:04PM  Celgenes Enterprise Value to Earnings in Line with Peers
11:41AM  Understanding Celgenes Premium PE Valuation
09:30AM  Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled
Sep-06-16 09:00AM  Syngene International Commissions Dedicated R&D Center for Amgen Business Wire
08:15AM  A $14,000 Price Tag For A Cholesterol Drug Can Be A Bargain at Forbes
07:55AM  Amgen Has Many Ways to Win
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc.; Advaxis, Inc.; and Dr. Reddy's Laboratories Ltd. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM